Femasys Inc. (FEMY) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.9x

Market Cap

$24.96M

MomentumView details →

1D Return

−2.61%

YTD Return

−74.05%

RSI (14)

49.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.9x

Market Cap

$24.96M

RSI (14)

49.4

MomentumView details →

1D Return

−2.61%

YTD Return

−74.05%

SummaryUpdated Jun 1, 2026

Femasys Inc. (NASDAQ:FEMY) is a biomedical company founded in 2004 and headquartered in Suwanee, Georgia, that specializes in developing and commercializing medical devices for women's healthcare. The company went public in June 2021 and focuses on creating innovative solutions for reproductive health, including permanent birth control, fertility treatments, and diagnostic procedures. Femasys operates in the medical devices sector, specifically targeting the underserved women's healthcare market with proprietary technologies designed to provide minimally invasive alternatives to traditional surgical procedures.

Ask drillr about Femasys Inc. →

ProfitabilityView details →

Gross Margin

52.16%

Net Margin

−534.27%

EBITDA Margin

−424.32%

ROE (TTM)

−304.78%

ROA (TTM)

−99.97%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

+21.86%

EPS YoY

+44.82%

FCF YoY

—

Revenue CAGR 3Y

+23.88%

EPS CAGR 3Y

+44.05%

EBITDA YoY

+46.79%

EarningsView details →

EPS (Actual)

−$1.33

EPS Surprise

−1.53%

Beats (12Q)

7/12

Next Q EPS Est

−$0.47

Avg Surprise (4Q)

51.72%

Rev Surprise

−54.59%

Capital & dividendView details →

Debt/Equity

1.19x

Current Ratio

2.14x

Quick Ratio

0.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.30M

Net Income (TTM)

−12.29M

Op. CF (TTM)

−17.65M

Next earningsNov 17, 2026 →

Latest newsMore news →

Femasys Inc. announced a partnership with UNC Health to introduce its fertility products FemVue, SpermVue, and FemaSeed Complete across UNC Health OB/GYN practice locations.9d ago

The U.S. Food and Drug Administration (FDA) authorized the modular premarket approval application pathway for Femasys's FemBloc non-surgical permanent birth control technology on Wednesday.16d ago

Similar companies

Harvard Bioscience, Inc.HBIO Jin Medical International Ltd.ZJYL Nephros, Inc.NEPH MOG Holdings Limited01942.HK Precision Optics Corporation, Inc.POCI Elegance Optical International Holdings Limited00907.HK Find similar companies →

Latest newsMore news →

Femasys Inc. announced a partnership with UNC Health to introduce its fertility products FemVue, SpermVue, and FemaSeed Complete across UNC Health OB/GYN practice locations.9d ago The U.S. Food and Drug Administration (FDA) authorized the modular premarket approval application pathway for Femasys's FemBloc non-surgical permanent birth control technology on Wednesday.16d ago